Physician profile
Celine Ord
NPI 1457526048
$1,053.49
in general payments reported to CMS, 2019-2025
22 companies · $716 in 2025
The $716 reported for 2025 was more than what 80% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.16 · 2020: $11.16 · 2022: $86.65 · 2023: $132 · 2024: $90.85 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $125.21 | 2024-2025 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $103.21 | 2023-2025 | Enhertu, Imfinzi |
| Regeneron Healthcare Solutions, INC. | $94.15 | 2024-2025 | Libtayo, Lynozyfic |
| Janssen Biotech, INC. | $72.47 | 2025 | Akeega, Balversa, Erleada |
| Celgene Corporation | $72.32 | 2023 | Pomalyst, Reblozyl |
| Siemens Medical Solutions USA, INC. | $65.78 | 2020-2022 | |
| Blue Earth Diagnostics | $63.52 | 2019-2025 | Posluma |
| Genzyme Corporation | $62.76 | 2025 | |
| Abbvie INC. | $57.36 | 2023-2025 | |
| Incyte Corporation | $46.07 | 2025 | Monjuvi, Zynyz, Niktimvo |
| Novartis Pharmaceuticals Corporation | $34.37 | 2025 | |
| Sobi, INC | $32.98 | 2025 | |
| Deciphera Pharmaceuticals INC. | $28.56 | 2025 | Romvimza |
| Tersera Therapeutics LLC | $28.12 | 2025 | Zoladex |
| Eisai INC. | $27.57 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $27.38 | 2025 | Loqtorzi |
| Pharmacosmos Therapeutics INC. | $23.66 | 2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $22.83 | 2025 | |
| Boston Scientific Corporation | $19.77 | 2022 | |
| Blueprint Medicines Corporation | $18.88 | 2025 | Ayvakit |
| Octapharma USA, INC. | $14.26 | 2023 | Octagam Immune Globulin (Human) |
| Foundation Medicine, INC. | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celine Ord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.